We spend hours hunched over phones and computer monitors day in and day out. It’s no surprise we have an epidemic of back ...

Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth ...

and changes in lumbar skeletal muscle index (LSMI). Patients (n=187) received either ponsegromab (100 mg, 200 mg or 400 mg) or placebo once every four weeks subcutaneously for 12 weeks.

Researchers have found that odanacatib (ODN), a cathepsin K (CatK) inhibitor, is an effective and safe treatment option for ...

In a new study published in Nature Communications, an international team of  researchers reveal new insights into the ...